Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 115(36): 9002-9007, 2018 09 04.
Artículo en Inglés | MEDLINE | ID: mdl-30127003

RESUMEN

Alzheimer's disease (AD) is characterized by the progressive destruction and dysfunction of central neurons. AD patients commonly have unprovoked seizures compared with age-matched controls. Amyloid peptide-related inflammation is thought to be an important aspect of AD pathogenesis. We previously reported that NLRP3 inflammasome KO mice, when bred into APPswe/PS1ΔE9 (APP/PS1) mice, are completely protected from amyloid-induced AD-like disease, presumably because they cannot produce mature IL1ß or IL18. To test the role of IL18, we bred IL18KO mice with APP/PS1 mice. Surprisingly, IL18KO/APP/PS1 mice developed a lethal seizure disorder that was completely reversed by the anticonvulsant levetiracetam. IL18-deficient AD mice showed a lower threshold in chemically induced seizures and a selective increase in gene expression related to increased neuronal activity. IL18-deficient AD mice exhibited increased excitatory synaptic proteins, spine density, and basal excitatory synaptic transmission that contributed to seizure activity. This study identifies a role for IL18 in suppressing aberrant neuronal transmission in AD.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloide/metabolismo , Inflamasomas/metabolismo , Interleucina-18/metabolismo , Convulsiones/metabolismo , Transmisión Sináptica , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Amiloide/genética , Animales , Inflamasomas/genética , Interleucina-18/genética , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Levetiracetam , Ratones , Ratones Noqueados , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Piracetam/análogos & derivados , Piracetam/farmacología , Convulsiones/tratamiento farmacológico , Convulsiones/genética , Convulsiones/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA